A hospital drug for rare oxygen-carrying failure of hemoglobin. Everyday energy, longer life, and Alzheimer's protection lack that footing; the best mouse test did not lengthen typical lifespan. Low amounts shuttle electrons in mitochondria; higher amounts block serotonin clearance, tighten vessels, and can stress red cells. Pharmaceutical-grade material, pre-dose enzyme test, and medicine review matter more than claimed energy benefit. (Full Review)

Protocol

Clinic microdose (Koniver and similar)

10–16 mg oral or buccal

In the morning, sometimes a few days per week. Practitioner custom, not a labeled dose.

Baseline biomarkers

G6PD, hemoglobin, eGFR, blood pressure

Confirm before the first dose; anemia or low eGFR argues for delay or avoidance.

Time of day

Morning

Peak plasma at 1–2 hours; 5–6 hour plasma half-life (terminal ~24 hours) leaves most of a morning dose cleared by night.

Time to effect

Reversal of methemoglobinemia

30–60 minutes

After standard 1–2 mg/kg intravenous dose

Residual bipolar depression and anxiety

Weeks

Mood moved over weeks on the six-month lamotrigine add-on regimen

Acute short-term memory retrieval in healthy adults

1 hour

After a large single oral dose in healthy adults

Benefits

High: Reversal of methemoglobinemia

Medium: Lower postoperative delirium and early cognitive dysfunction; Residual bipolar depression and anxiety; Vasodilatory and septic shock; Antimalarial activity

Low: Acute short-term memory retrieval in healthy adults; Skin fibroblast vigor in laboratory models; Rescue of ifosfamide-induced encephalopathy; Alzheimer's disease modification

Speculative: Human lifespan extension; Everyday energy in healthy adults

Contraindications

G6PD deficiency (any activity class)

SSRIs (fluoxetine, sertraline, escitalopram, paroxetine, fluvoxamine, citalopram; washout typically 2 weeks, 5 weeks for fluoxetine)

SNRIs and related (venlafaxine, desvenlafaxine, duloxetine, vortioxetine)

Tricyclic and related antidepressants (amitriptyline, imipramine, nortriptyline, mirtazapine, trazodone; washout typically 2 weeks)

Linezolid

MAOIs (phenelzine, tranylcypromine, isocarboxazid, selegiline; washout typically 14 days)

Pregnancy and breastfeeding (label contraindication)

Known hypersensitivity to thiazine dyes

Severe renal impairment (eGFR <30 mL/min/1.73 m²) unless a hospital indication forces a reduced intravenous dose

Infants, especially if G6PD status is unknown

Uncontrolled severe hypertension

Key Interactions

Some opioids (tramadol, meperidine, fentanyl, methadone; caution to contraindication)

Bupropion (caution to contraindication)

Triptans, triptan-like agents, and cyclobenzaprine

Over-the-counter dextromethorphan

St. John's wort, 5-hydroxytryptophan (5-HTP), L-tryptophan, S-adenosylmethionine (SAMe)

Red-light or photodynamic devices

Nitrates and nitric-oxide donors (nitroglycerin, sodium nitroprusside)

Other mitochondrial redox agents (coenzyme Q10, idebenone)

Risk & Side Effects

High: Serotonin toxicity with serotonergic drugs; Hemolysis, especially in G6PD deficiency; Blue-green discoloration of urine, stool, and tissues

Medium: Paradoxical methemoglobinemia at high dose; Photosensitivity and phototoxicity; Gastrointestinal symptoms; Raised arterial pressure and vasopressor-like tone; Spurious pulse oximetry and laboratory interference

Low: Anaphylaxis to injected blue dye; Headache, dizziness, and dysgeusia; Leg cramps

Speculative: Harm from industrial or aquarium-grade impurities; Chronic sleep or mood disruption from MAO-A inhibition

Monitoring

Marker	Target	Why
G6PD activity	Within the laboratory's normal band; any deficiency is an exclusion	Identifies hemolysis risk before the first dose
Hemoglobin / CBC	Men 13.5–15.5 g/dL; women 12.5–14.5 g/dL	Detects hemolysis
Methemoglobin	<1.5%	Detects paradoxical methemoglobinemia
eGFR / creatinine	eGFR >90 mL/min/1.73 m² preferred	Renal clearance of parent drug and Azure B
Sitting blood pressure	~110–125 / 70–80 mmHg	Detects the pressor effect

Cadence: First-dose check of urine color, nausea, and blood pressure at 1–2 hours; complete blood count and eGFR at 4 weeks, then every 3–6 months, with blood pressure at each interval and after any dose increase

Qualitative Assessment

Morning mental clarity and working-memory ease versus baseline
Sleep onset and sleep continuity after a morning-only schedule
Resting energy and training recovery without agitation
Skin photosensitivity after outdoor time or light devices
Expected blue-green urine without pain, clot, or falling hemoglobin

Methylene Blue for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment